But while many people have reported significant relief using the CGRP monoclonal antibodies (mAbs) and gepants, others have experienced little to no relief. If these CGRP-targeting treatments are ...

There are also four monoclonal antibodies targeting CGRP activity for the prevention of migraine attacks. These are erenumab-aooe (Aimovig), galcanezumab (Emgality), fremanezumab (Ajovy), and ...

Merck has announced that the antagonist of the calcitonin gene-related peptide (CGRP) receptor telcagepant has met the primary end points in two Phase III trials to treat migraine, which is ...

The decision means that with two CGRP antibodies now cleared for migraine prevention, the first drug in the class to be approved in Europe – Novartis’ Aimovig (erenumab) – has fallen further ...

Medscape Medical News, January 24, 2025 More Research Backs Migraine Meds as Heart Safe Anti-CGRP antibodies vs onabotulinumtoxinA is not associated with increased cardiovascular disease risk in ...

and with it eptinezumab – a humanised anti-calcitonin gene-related peptide (CGRP) monoclonal antibody. Eptinezumab was approved by the United States Food and Drug Administration (FDA ...

The decision means that with two CGRP antibodies now cleared for migraine prevention, the first drug in the class to be approved in Europe – Novartis’ Aimovig (erenumab) – has fallen further ...